On February 19, 2024, andecaliximab, a highly selective antibody inhibitor of MMP9, was granted orphan drug designation by the European Medicines Agency (EMA). Learn more On March 19, 2024, the U.S. Food & Drug Administration (FDA) also granted andecaliximab orphan drug designation. Learn more It is important to remember that requesting regulators like the EMA and FDA […]
